Sign In
Buy DNA
$7.89
-0.110 (-1.38%)
At Close: Jun 12, 2026
Il Granaio delle Idee and Ginkgo Bioworks Announce Strategic Collaboration to Optimize Sourdough Strains for Bakery Products
07:02am, Tuesday, 16'th Apr 2024
IGDI will leverage Ginkgo's Adaptive Laboratory Evolution technology to improve its sourdough starter culture product PADUA, Italy and BOSTON , April 16, 2024 /PRNewswire/ -- Il Granaio delle Idee (IG
Novo Nordisk and Ginkgo Bioworks Are Teaming Up. Here's Why That's Bullish for Both Stocks.
10:00am, Monday, 15'th Apr 2024
Novo Nordisk and Ginkgo Bioworks will work together on manufacturing. Producing more obesity and diabetes medicines is likely a priority.
Modalis Announces Partnership with Ginkgo Bioworks
02:05am, Friday, 12'th Apr 2024
TOKYO & WALTHAM, Mass.--(BUSINESS WIRE)--Modalis Therapeutics Corporation (Modalis) (Tokyo Stock Exchange: 4883) announced that it has entered into an agreement with Ginkgo Bioworks (Ginkgo) to join t
Ginkgo Bioworks Announces Acquisition of AgBiome's Platform Assets
07:01am, Thursday, 11'th Apr 2024
BOSTON , April 11, 2024 /PRNewswire/ -- Today, Ginkgo Bioworks (NYSE: DNA ), which is building the leading platform for cell programming and biosecurity, announced the acquisition of AgBiome's platfo
Bull Market and Beyond: 3 Stocks Just Waiting to Soar
04:50am, Tuesday, 09'th Apr 2024
These biotech stocks have missed out on market gains so far, falling in the double digits over the past year. But they are innovators with potential growth catalysts right around the corner.
2 Stocks That Could More Than Double Your Money, According to Wall Street: Are They Buys Now?
04:19am, Wednesday, 03'rd Apr 2024
Analyst price targets for a pair of biotech stocks suggest they can more than double your money over the next 12 months. B. Riley recently lowered expectations for Ginkgo Bioworks, but its new target
AI2 Incubator spinout Modulus sells cell therapy tech assets to Boston's Ginkgo Bioworks
05:54pm, Tuesday, 02'nd Apr 2024
The news: Modulus Therapeutics, a Seattle-based cellular therapy company spun out of the Allen Institute of Artificial Intelligence (AI2) Incubator, has sold its cell therapy platform assets to the Bo
Sizing Your Penny Stocks Position, 3 Tips
06:26am, Sunday, 31'st Mar 2024
Sizing positions correctly is a cornerstone of successful investing, especially when dealing with penny stocks. The unique nature of penny stocks, with their potential for substantial gains, requires
Is Ginkgo Bioworks Stock a Buy?
05:07pm, Friday, 15'th Mar 2024
Ginkgo Bioworks is trying to make good on its promises of scaling up. It's adding plenty of new programs, but its revenue is lagging.
3 Pharmaceutical Stocks to Buy Hand Over Fist in March
09:28am, Monday, 11'th Mar 2024
Pfizer is a rebound candidate that pays a hefty dividend while you wait. AbbVie has been broadening its product offerings to become more diversified.
Is Ginkgo Bioworks Destined to Be in a "Magnificent Seven" of Healthcare Stocks?
12:45pm, Sunday, 03'rd Mar 2024
Ginkgo Bioworks is aiming to play a key role in drug development. And there's a solid argument for why it could be hugely successful one day.
Why Ginkgo Bioworks Stock Is Sinking Today
12:21pm, Friday, 01'st Mar 2024
Ginkgo Bioworks' fourth-quarter results missed Wall Street's revenue and earnings estimates. The company's full-year 2024 revenue guidance was also well below analysts' consensus estimate.
Ginkgo Bioworks Holdings, Inc. (DNA) Reports Q4 Loss, Misses Revenue Estimates
07:21pm, Thursday, 29'th Feb 2024
Ginkgo Bioworks Holdings, Inc. (DNA) came out with a quarterly loss of $0.09 per share in line with the Zacks Consensus Estimate. This compares to loss of $0.04 per share a year ago.
Is Ginkgo Bioworks Stock a Buy Now?
08:30am, Saturday, 24'th Feb 2024
Ginkgo's cell programming process helps businesses launch products and improve existing processes. The company has partnered with many top names in the healthcare industry for this purpose.
2 Top Biotech Stocks That Wall Street Thinks Could Soon Double in Value
02:59am, Friday, 23'rd Feb 2024
Analysts are bullish, on average, regarding both Ginkgo Bioworks and Iovance Biotherapeutics. Ginkgo Bioworks' cost-cutting and manufacturing scaling capabilities are being put to the test.
